Aprea Therapeutics logo

Aprea TherapeuticsNASDAQ: APRE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 October 2019

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$23.25 M
-79%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-59%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Mon, 28 Oct 2024 13:30:00 GMT
$4.28+$0.38(+9.74%)

Dividend

No data over the past 3 years
$250.00 K$220.00 K

Analysts recommendations

Institutional Ownership

APRE Latest News

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
globenewswire.com14 October 2024 Sentiment: POSITIVE

DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024.

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
globenewswire.com09 October 2024 Sentiment: POSITIVE

DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor.

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
zacks.com12 August 2024 Sentiment: POSITIVE

Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.87 per share a year ago.

Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
Zacks Investment Research24 April 2023 Sentiment: POSITIVE

Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

What type of business is Aprea Therapeutics?

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-cancer drugs that reactivate the mutant tumor suppressor protein p53. Its lead candidate product, APR-246, is a low molecular weight reactivator of p53 that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The company was founded in 2006 and is headquartered in Boston, Massachusetts.

What sector is Aprea Therapeutics in?

Aprea Therapeutics is in the Healthcare sector

What industry is Aprea Therapeutics in?

Aprea Therapeutics is in the Biotechnology industry

What country is Aprea Therapeutics from?

Aprea Therapeutics is headquartered in United States

When did Aprea Therapeutics go public?

Aprea Therapeutics initial public offering (IPO) was on 03 October 2019

What is Aprea Therapeutics website?

https://www.aprea.com

Is Aprea Therapeutics in the S&P 500?

No, Aprea Therapeutics is not included in the S&P 500 index

Is Aprea Therapeutics in the NASDAQ 100?

No, Aprea Therapeutics is not included in the NASDAQ 100 index

Is Aprea Therapeutics in the Dow Jones?

No, Aprea Therapeutics is not included in the Dow Jones index

When was Aprea Therapeutics the previous earnings report?

No data

When does Aprea Therapeutics earnings report?

The next expected earnings date for Aprea Therapeutics is 08 November 2024